Press Releases

4D Molecular Therapeutics Enrolls First Patient in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA, December 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in gene therapy product discovery and development, today announced the enrollment of the first participant in its Choroideremia Natural History Study (NHS). This study is an important step in developing a groundbreaking gene therapy product optimized for intravitreal administration to treat Choroideremia (CHM) patients. 4DMT has deployed its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to create and optimize a proprietary AAV vector for intravitreal delivery to the retina. This vector is designated to be the basis for the first 4DMT experimental gene therapeutic targeted for the treatment of CHM. 4DMT is working in close collaboration with the Choroideremia Research Foundation on CHM product development and the Natural History Study. Choroideremia Natural History Study (NHS) Purpose The NHS is a multi-center US-based study designed to evaluate disease

Continue reading

4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA, February 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, and the Choroideremia Research Foundation (CRF), a non-profit dedicated to finding a cure for choroideremia, today announced a partnership to develop a gene therapy product optimized for intravitreal administration to treat Choroideremia. Under the terms of the agreement, CRF will provide 4DMT funding to deploy its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to create and optimize a proprietary AAV vector for intravitreal delivery to the retina. This vector will be the basis of a 4DMT experimental gene therapeutic that will be evaluated and developed by 4DMT in close collaboration with the CRF. “We believe that 4D’s Therapeutic Vector Evolution approach to AAV vector design, which creates a vector with the ability to successfully penetrate the retina

Continue reading

4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development

Leader in proprietary gene therapy vector discovery closes fifth partnership Emeryville, CA, Jan 7, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and a collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to discover and develop targeted and proprietary next-generation AAV vectors for cardiac disease indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to potentially identify and optimize novel gene delivery vectors for use in potential cardiac gene therapy products. Key terms of the agreements include an equity investment by Pfizer, an upfront license payment to 4DMT and potential development and commercial milestone payments plus tiered royalties to 4DMT on net sales of any potential products that result from this collaboration. Pfizer has also committed to an additional investment in a future

Continue reading

4D Molecular Therapeutics and Roche sign collaboration agreement for gene therapy vector discovery and product development

San Francisco, CA, April 27, 2015 — 4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development today announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for use in gene therapy products. Financial details were not disclosed.

AGTC and 4DMT Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development

SAN FRANCISCO and GAINESVILLE, Fla. – April 20, 2015 — Applied Genetic Technologies Corporation (Nasdaq: AGTC) and 4D Molecular Therapeutics (4DMT), leaders in next-generation adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors. Financial details were not disclosed.   Sue Washer, President and CEO of AGTC, noted, “We are excited to partner with 4DMT to accelerate development of novel AAV-based gene therapies to treat rare eye diseases. We expect that our combined expertise and our complementary proprietary technology and discovery platforms, will enable us to advance new treatments to market for patients with serious inherited ocular conditions who have few currently

Continue reading